Publications

BibTex format

@article{Freudenthal:2016:10.1016/j.clon.2016.12.011,
author = {Freudenthal, B and Williams, GR},
doi = {10.1016/j.clon.2016.12.011},
journal = {Clinical Oncology},
pages = {325--328},
title = {TSH suppression in the long-term follow-up of differentiated thyroid cancer},
url = {http://dx.doi.org/10.1016/j.clon.2016.12.011},
volume = {29},
year = {2016}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Differentiated  thyroid  cancer  is  the  commonest  form  of  thyroid  cancer,  and  its  prognosis  is favourable  in  the  majority  of  cases.  Suppression  of  thyroid  stimulating  hormone  (TSH)  by  supra-physiological  thyroid hormone  replacement  has  been  the  mainstay  of  long-term  management  for over  60  years.  However,  evidence  for  a  beneficial  outcome  of  TSH  suppression  is  conflicting  and intervention  must  be  balanced  against  adverse  effects,  particularly  affecting  the  cardiovascular system and skeleton. Here we discuss the role of TSH suppression in the long-term management of differentiated thyroid cancer in the context of risk-stratification for disease recurrence and the latest clinical guidelines.
AU  - Freudenthal,B
AU  - Williams,GR
DO  - 10.1016/j.clon.2016.12.011
EP  - 328
PY  - 2016///
SN  - 0936-6555
SP  - 325
TI  - TSH suppression in the long-term follow-up of differentiated thyroid cancer
T2  - Clinical Oncology
UR  - http://dx.doi.org/10.1016/j.clon.2016.12.011
UR  - http://hdl.handle.net/10044/1/43394
VL  - 29
ER  -

Download

ProfessorGrahamWilliams

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)